Dr Aris Angelis
Chair of the Greek Committee for Health Technology Assessment (HTA)
Dr Aris Angelis is Chair of the Greek Committee for Health Technology Assessment (HTA) and Reimbursement, Advisor to the Minister of Health, and Greece’s representative on the European Medicines Agency’s Committee for Medicinal Products for Human Use. He leads the continued development of Greece’s national HTA and reimbursement system, focusing on institutional governance, evidence-informed decision-making, implementation of the EU HTA Regulation, and sustainable access to effective health technologies.
His international roles include serving as Greece’s delegate to the Heads of HTA Agencies Group and the OECD Health Committee, and as a member of the Steering Committee of the World Health Organization’s Novel Medicines Platform.
Previously, Dr Angelis served for three years as Greece’s first Secretary General for Strategic Planning at the Ministry of Health, reporting directly to the Minister. He led national policy and major reforms across pharmaceuticals, reimbursement, digital health and strategic planning, including measures supported by the Recovery and Resilience Facility. As a member of the Ministry’s senior leadership, he represented Greece in European negotiations and policy forums, including the EU Employment, Social Policy, Health and Consumer Affairs Council, and contributed to negotiations on major European pharmaceutical, medicines-security and health-data legislation.
Before entering government, Dr Angelis was Assistant Professor of Health Economics at the London School of Hygiene & Tropical Medicine, where he remains a Visiting Associate Professor. He previously held research and teaching positions at the London School of Economics and Political Science.
His research and advisory experience includes work for the European Commission, the World Health Organization and national health ministries. He has published more than 35 peer-reviewed papers, attracting over 3,000 citations, including work in The BMJ, The Lancet Oncology, Nature Medicine and the American Journal of Public Health. He was a NICE Scholar in 2021–2022.
Dr Angelis holds a PhD in Health Policy and Economics and an MSc in International Health Policy from the London School of Economics, an MSc in Biopharmacy from King’s College London, and a BSc in Biochemistry from Imperial College London.